No Impact of Prophylactic Corticosteroid Use in Patients Receiving Axicabtagene Ciloleucel for Large B-Cell Lymphoma

被引：0
|
作者：
Melody, Megan [1 ,2 ]
Franco, Stephanie [3 ]
Odetola, Oluwatobi [1 ,2 ]
Lin, Adam [1 ,2 ]
Moreira, Jonathan [1 ,2 ]
Carson, Kenneth [1 ,2 ]
Ma, Shuo [1 ,2 ]
Winter, Jane N. [1 ,2 ]
Gordon, Leo [1 ,2 ]
Karmali, Reem [1 ,2 ]
机构：
[1] Northwestern Univ, Feinberg Sch Med, Dept Med, Div Hematol Oncol, Chicago, IL USA
[2] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA
[3] Northwestern Univ, Feinberg Sch Med, Dept Med, Chicago, IL USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
CT; LBCL; CAR T-cell therapy; CRS; ICANS;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT-630
引用
收藏
页码：S611 / S612
页数：2
相关论文
共 50 条
  • [1] Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States
    Roth, Joshua A.
    Sulliyan, Sean D.
    Lin, Vincent W.
    Bansal, Aasthaa
    Purdum, Anna G.
    Nayale, Lynn
    Cheng, Paul
    Ramsey, Scott D.
    JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (12) : 1238 - 1245
  • [2] Outcomes and factors impacting use of axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma: results from an intention-to-treat analysis
    Mian, Agrima
    Wei, Wei
    Winter, Allison M.
    Khouri, Jack
    Jagadeesh, Deepa
    Anwer, Faiz
    Gerds, Aaron T.
    Dean, Robert M.
    Sobecks, Ronald
    Pohlman, Brad
    Hamilton, Betty K.
    Majhail, Navneet S.
    Hill, Brian T.
    LEUKEMIA & LYMPHOMA, 2021, 62 (06) : 1344 - 1352
  • [3] An updated cost-effectiveness analysis of axicabtagene ciloleucel in second-line large B-cell lymphoma patients in the United States
    Oluwole, Olalekan O.
    Patel, Anik R.
    Vadgama, Sachin
    Smith, Nathaniel J.
    Blissett, Rob
    Feng, Chaoling
    Dickinson, Michael
    Johnston, Patrick B.
    Perales, Miguel-Angel
    JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 77 - 83
  • [4] Single-Center Experience of Axicabtagene Ciloleucel CAR-T Cell Therapy in Relapsed/Refractory Large B-Cell Lymphoma
    Melody, Megan
    Rahman, Zaid Abdel
    Ernesto, Ayala
    Gannon, Nicole
    Roy, Vivek
    Sher, Taimur
    Ailawadhi, Sikander
    Foran, James
    Dabaja, Mohamed Kharfan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S267 - S268
  • [5] Axicabtagene Ciloleucel versus Tisagenlecleucel for Relapsed or Refractory Large B Cell Lymphoma: A Systematic Review and Meta-Analysis
    Gagelmann, Nico
    Bishop, Michael
    Ayuk, Francis
    Bethge, Wolfgang
    Glass, Bertram
    Sureda, Anna
    Pasquini, Marcelo C.
    Kroeger, Nicolaus
    TRANSPLANTATION AND CELLULAR THERAPY, 2024, 30 (06): : 584.e1 - 584.e13
  • [6] Retreatment (reTx) of Patients with Refractory Large B Cell Lymphoma with Axicabtagene Ciloleucel (Axi-Cel) in ZUMA-1
    Locke, Frederick L.
    Bartlett, Nancy L.
    Jacobson, Caron A.
    Oluwole, Olalekan O.
    Munoz, Javier
    Lekakis, Lazaros J.
    Topp, Max S.
    Avivi, Irit
    Kim, Jenny J.
    Chu, Rong
    Zheng, Lianqing
    Rossi, John M.
    Bot, Adrian
    Neelapu, Sattva S.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S265 - S265
  • [7] Durability of Response in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel in the Pivotal Phase 2 Study, ZUMA-1
    Locke, Frederick L.
    Ghobadi, Armin
    Jacobson, Caron A.
    Jacobsen, Eric
    Miklos, David B.
    Lekakis, Lazaros J.
    Braunschweig, Ira
    Oluwole, Olalekan O.
    Lin, Yi
    Siddiqi, Tanya
    Deol, Abhinav
    Reagan, Patrick M.
    Farooq, Umar
    Bot, Adrian
    Jiang, Yizhou
    Rossi, John M.
    Xue, Allen
    Go, William Y.
    Neelapu, Sattva S.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S277 - S278
  • [8] Axicabtagene Ciloleucel in Patients with Refractory Large B Cell Lymphoma: Outcomes by Prior Lines of Therapy in the Pivotal Phase 2 Study, ZUMA-1
    Locke, Frederick L.
    Ghobadi, Armin
    Lekakis, Lazaros J.
    Miklos, David B.
    Jacobson, Caron A.
    Jacobsen, Eric
    Braunschweig, Ira
    Oluwole, Olalekan O.
    Siddiqi, Tanya
    Lin, Yi
    Reagan, Patrick M.
    Farooq, Umar
    Deol, Abhinav
    Bot, Adrian
    Rossi, John M.
    Jiang, Yizhou
    Xue, Allen
    Go, William Y.
    Neelapu, Sattva S.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S276 - S276
  • [9] Axicabtagene Ciloleucel (Axi-Cel) In Patients With Refractory Large B Cell Lymphoma: Long-Term Safety and Efficacy of ZUMA-1
    Neelapu, S. S.
    Ghobadi, A.
    Jacobson, C. A.
    Miklos, D. B.
    Lekakis, L. J.
    Oluwole, O. O.
    Lin, Y.
    Braunschweig, I.
    Hill, B. T.
    Timmerman, J. M.
    Deol, A.
    Reagan, P. M.
    Stiff, P.
    Flinn, I. W.
    Farooq, U.
    Goy, A.
    McSweeney, P. A.
    Munoz, J.
    Siddiqi, T.
    Chavez, J. C.
    Herrera, A. F.
    Xue, A.
    Jiang, Y.
    Bot, A.
    Rossi, J. M.
    Kim, J. J.
    Go, W. Y.
    Locke, F. L.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 26 - 27
  • [10] Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium
    Jacobs, Miriam T.
    Jain, Michael D.
    Gao, Feng
    Nastoupil, Loretta J.
    Spiegel, Jay Y.
    Lin, Yi
    Dahiya, Saurabh
    Lunning, Matthew
    Lekakis, Lazaros
    Reagan, Patrick M.
    Oluwole, Olalekan O.
    McGuirk, Joseph
    Deol, Abhinav
    Sehgal, Alison
    Goy, Andre
    Hill, Brian T.
    Andreadis, Charalambos
    Munoz, Javier
    Chavez, Julio C.
    Bennani, N. Nora
    Rapoport, Aaron P.
    Vose, Julie M.
    Miklos, David B.
    Neelapu, Sattva S.
    Ghobadi, Armin
    Locke, Frederick L.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (10) : 753 - 759
12345